Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.

Wanbury Limited Re?d. Office : BSEL Tech Park, B-wing 10' Floor, Sector-30 A, Opp. Vashi Railway Station, Vashi Navi Mumbai 400 703 Maharashtra, INDIA Tel. : +91-22-6794 2222 +91-22-7196 3222 .( WANBURY CIN L51900MH1988PLC048455 Email : info@wanbury.com Website : www.wanbury.com August 13, 2026 BSE Limited National Stock Exchange of India Ltd, PJ. Towers, Exchange Plaza, Dalal Street Bandra Kurla Complex, Mumbai - 400 001. Bandra (East), Mumbai -400 051. Script Code: 524212 Script Code: W ANBURY Dear Sir /Madam, Sub.: Press Release regarding EDOM Approval for new product Rivaroxaban API, USFDA DMF Clearances. Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under: W anbury Limited received approval from the office of European Directorate for the Quality of Medicines and Healthcare (EDQM) for new product Rivaroxaban API recently which will enable to meet customer demand of EU and other countries accepting CEP. The Company also received DMF clearance for Paraxetine HCI and for Metformin HCI from the office of USFDA while ANDA review for multiple customers. This is for your information and record. Thanking you. Yours faithfully, For Wanbury Ltd Jitendra J. Gandhi Company Secretary